Helix BioMedix, Inc. (HXBM)
- Previous Close
23.27 - Open
23.25 - Bid --
- Ask --
- Day's Range
23.27 - 23.27 - 52 Week Range
23.00 - 23.36 - Volume
6 - Avg. Volume
6 - Market Cap (intraday)
5.8M - Beta (5Y Monthly) 0.35
- PE Ratio (TTM)
-- - EPS (TTM)
-11.64 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Helix BioMedix, Inc. operates as a specialty dermatology and consumer products skin health company in the United States. It develops and commercializes bioactive peptides, including anti-infective, anti-fungal, and anti-inflammatory peptides for the treatment of skin and wound infections, as well as for the prevention of staphylococcus aureus infections. The company also out-licenses its proprietary peptides to various entities. Helix BioMedix, Inc. was founded in 1988 and is headquartered in Bothell, Washington.
www.helixbiomedix.comRelated News
Performance Overview: HXBM
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HXBM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HXBM
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
3.45
Enterprise Value/EBITDA
-3.06
Financial Highlights
Profitability and Income Statement
Profit Margin
-125.06%
Return on Assets (ttm)
-59.00%
Return on Equity (ttm)
-122.53%
Revenue (ttm)
2.07M
Net Income Avi to Common (ttm)
-2.58M
Diluted EPS (ttm)
-11.64
Balance Sheet and Cash Flow
Total Cash (mrq)
216.53k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.08M